US: Pharmaceuticals
More
-
May 7- Three months ended March 31. Net Profit 1.69 vs 1.23 Net Sales 6.32 vs 6.23 EPS 20.0 vs 14.5 Results are standalone NOTE: GlaxoSmithKline Pharmaceuticals Ltd is a drugmaker. *Source text:* Further company coverage ().
-
*Established drug products in focus at Pfizer, GSK, Sanofi. Bankers speaking at the Reuters Health Summit said the success of transactions such as Pfizer Inc's divestitures of noncore assets and Abbott Laboratories splitting off its innovative drugs into AbbVie Inc had fuelled a wider rethink across the industry.
-
Saurabh Mukherjea, Head of Equities at Ambit Capital talks to Cash Flow about where to invest in India's pharmaceutical market.
-
May 6- Eli Lilly& Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the potentially dangerous condition and return to work this summer, the drugmaker said on Monday.
-
May 6- Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer. Chief Financial Officer Derica Rice will serve as acting CEO while Lechleiter recuperates, as per the company bylaws.
-
LONDON, May 6- Scientists have worked out the way in which stress hormones reduce the number of new brain cells- a process linked to depression- and say their work should help researchers develop more effective antidepressants.
-
BRUSSELS, May 6- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --RAG trust and buyout firm CVC Capital Partners to sell part of their shares in German chemicals company Evonik Industries.
-
FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
*Aiming to win bigger slice of growing market* Lilly currently No.4 in $40 bln diabetes market* Lilly says mainly addressing GPs, not specialists By Ludwig Burger and Frank Siebelt. FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
BRUSSELS, May 3- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --RAG trust and buyout firm CVC Capital Partners to sell part of their shares in German chemicals company Evonik Industries.
-
May 3- Three months ended March 31. Net Loss 158.8 vs 330.0 Net Sales 948.5 vs 916.9 Loss per share 7.43 vs 13.20 Results are standalone NOTE: AstraZeneca Pharma Ltd is a drug manufacturer. *Source text:* Further company coverage ().
-
Lawyers with the Justice Department filed the appeal with the 2nd U.S. Circuit Court of Appeals in New York, according to court documents. District Judge Edward Korman's ruling from April 5 that required the FDA to make the emergency contraception available over-the-counter to women of all ages within 30 days.
-
May 2- Mylan Inc on Thursday reported slightly higher-than-expected first-quarter profit as sales were boosted by demand for its generic drugs in Europe and the Asia/Pacific regions. The generic drugmaker said net profit fell to $106.9 million, or 27 cents per share, compared with profit of $129.1 million, or 30 cents per share, a year earlier.
-
May 2- Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.
-
May 2- Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.
-
May 2- Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.
-
May 2- Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.
-
An antibiotic-resistant strain of gonorrhea has some saying that its effects could match those of AIDS.